OVERVIEW

This program covers the latest topics in cardiovascular and metabolic disease, guidelines, late-breaking clinical trial results, and addresses patient care issues encountered in daily practice.

It is being held as a three session series:

SESSION 1 : Wednesday, May 25, 2022 – 8:00 - 9:40 pm EST

GLP-1 agonists: underused and underappreciated? -Darren McGuire
CKD: save the kidneys, save the heart -David Cherney
Stable CAD: when to use antianginals and when to revascularize - Tara Sedlak
Stable CAD: ASA alone, prolonged DAPT or low-dose rivaroxaban?
Discussion and Q+A -All Faculty

Learning objectives:

• Explore current role of GLP-1 agonists in clinical practice
• Recognize the impact of kidney protection for cardiac protection
• Determine when to use medical vs surgical treatment in stable CAD
• Describe appropriate antiplatelet therapy for stable CAD patients

SESSION 2 : Wednesday, June 1, 2022 - 8:00 - 9:40 pm EST

Have we entered a new era in obesity management?- Sue Pedersen
When to use ezetimibe or PCSK9 inhibitors in secondary prevention- Jacques Genest
Inclisiran: the new LDL kid on the block- Milan Gupta
Cardiovascular risk reduction: more than just LDL-C- Deepak Bhatt
Discussion and Q+A -All Faculty

Learning objectives:

• Describe a guidelines centric approach to manage and support patients with obesity
• Distinguish the appropriate use of ezetimibe or PCSK9 inhibitors in secondary prevention
• Discuss the role of a new market entrance in lipid management
• Apply guideline centric strategies for managing cardiovascular risk beyond LDL-C

SESSION 3 : Wednesday, June 8, 2022 - 8:00 - 9:40 pm EST

Lessons learned after a decade of experience with DOAC’s- Paul Dorian
HFrEF: how to start and titrate the four pillars of treatment - Nadia Giannetti
HFpEF: which drugs have become standard of care? - Milan Gupta
CV medicine in the next decade: predicting the future - Deepak Bhatt
Discussion and Q+A - All Faculty

Learning objectives:

• Summarize the benefits and challenges with using DOAC's
• Describe appropriate management strategies and therapies for managing patients with HFrEF and HFpEF
• Explore developments in cardiovascular medicine that may change how we treat patients in the future

TARGET AUDIENCE

This program is intended for family physicians.

ACCREDITATION

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.

 For more informations please visit the official event page.